JP2020507596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507596A5 JP2020507596A5 JP2019543851A JP2019543851A JP2020507596A5 JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5 JP 2019543851 A JP2019543851 A JP 2019543851A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- subject
- pharmaceutical composition
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216425A JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Division JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507596A JP2020507596A (ja) | 2020-03-12 |
| JP2020507596A5 true JP2020507596A5 (https=) | 2021-04-01 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (https=) |
| EP (1) | EP3582805A4 (https=) |
| JP (2) | JP2020507596A (https=) |
| KR (3) | KR20190117014A (https=) |
| CN (2) | CN110290803A (https=) |
| AU (2) | AU2018221822A1 (https=) |
| CA (1) | CA3052652A1 (https=) |
| EA (1) | EA201991870A1 (https=) |
| IL (3) | IL302777A (https=) |
| MA (1) | MA47509A (https=) |
| SG (1) | SG11201907211TA (https=) |
| WO (1) | WO2018152415A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3142751T (pt) * | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| SG11201907211TA (en) * | 2017-02-16 | 2019-09-27 | Medimmune Llc | Anti-pd-l1 antibody treatment of bladder cancer |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| EP4153783A1 (en) * | 2020-05-21 | 2023-03-29 | Astrazeneca AB | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma |
| US20250388678A1 (en) * | 2024-06-25 | 2025-12-25 | Astrazeneca Ab | Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| PT3142751T (pt) * | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| NZ733854A (en) * | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| JP7144935B2 (ja) * | 2015-05-29 | 2022-09-30 | ジェネンテック， インコーポレイテッド | 癌のための治療方法及び診断方法 |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| SG11201907211TA (en) * | 2017-02-16 | 2019-09-27 | Medimmune Llc | Anti-pd-l1 antibody treatment of bladder cancer |
-
2018
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507596A5 (https=) | ||
| Guan et al. | Adverse events of monoclonal antibodies used for cancer therapy | |
| Chen et al. | Adverse effects of anticancer agents that target the VEGF pathway | |
| JP2018522850A5 (https=) | ||
| Soularue et al. | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study | |
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| US20200002428A1 (en) | Treatment of c1013g/cxcr4-associated waldenstrom's macroglobulinemia with an anti-cxcr4 antibody | |
| CN108498532A (zh) | 骨髓抑制的治疗 | |
| JP2024038034A5 (https=) | ||
| Lignon et al. | Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma | |
| Hyung et al. | Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| Rose et al. | A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study | |
| Fujimoto et al. | A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| Nardi et al. | FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study | |
| Kojima et al. | Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors | |
| Umemura et al. | Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| Uranga et al. | Gastrointestinal side effects of anticancer therapy | |
| Shukuya et al. | Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients | |
| Schieber et al. | Tarlatamab rechallenge after grade 3 cytokine release syndrome leading to tumor regression in two weeks and reopening of a collapsed lung: a case report | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| JPWO2020223702A5 (https=) | ||
| US20170095492A1 (en) | Method of treating ovarian, tubal and peritoneal cancer |